BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 22555163)

  • 1. Histone methyltransferase inhibitors induce HIV-1 recovery in resting CD4(+) T cells from HIV-1-infected HAART-treated patients.
    Bouchat S; Gatot JS; Kabeya K; Cardona C; Colin L; Herbein G; De Wit S; Clumeck N; Lambotte O; Rouzioux C; Rohr O; Van Lint C
    AIDS; 2012 Jul; 26(12):1473-82. PubMed ID: 22555163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suppression of HIV replication in the resting CD4+ T cell reservoir by autologous CD8+ T cells: implications for the development of therapeutic strategies.
    Chun TW; Justement JS; Moir S; Hallahan CW; Ehler LA; Liu S; McLaughlin M; Dybul M; Mican JM; Fauci AS
    Proc Natl Acad Sci U S A; 2001 Jan; 98(1):253-8. PubMed ID: 11136258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nicotinamide activates latent HIV-1 ex vivo in ART suppressed individuals, revealing higher potency than the association of two methyltransferase inhibitors, chaetocin and BIX01294.
    Samer S; Arif MS; Giron LB; Zukurov JPL; Hunter J; Santillo BT; Namiyama G; Galinskas J; Komninakis SV; Oshiro TM; Sucupira MC; Janini LM; Diaz RS
    Braz J Infect Dis; 2020; 24(2):150-159. PubMed ID: 32105620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection.
    Reuse S; Calao M; Kabeya K; Guiguen A; Gatot JS; Quivy V; Vanhulle C; Lamine A; Vaira D; Demonte D; Martinelli V; Veithen E; Cherrier T; Avettand V; Poutrel S; Piette J; de Launoit Y; Moutschen M; Burny A; Rouzioux C; De Wit S; Herbein G; Rohr O; Collette Y; Lambotte O; Clumeck N; Van Lint C
    PLoS One; 2009 Jun; 4(6):e6093. PubMed ID: 19564922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human immunodeficiency virus type 1 (HIV-1) antigen secretion by latently infected resting CD4+ T lymphocytes from HIV-1-infected individuals.
    Fondere JM; Petitjean G; Huguet MF; Salhi SL; Baillat V; Macura-Biegun A; Becquart P; Reynes J; Vendrell JP
    J Virol; 2004 Oct; 78(19):10536-42. PubMed ID: 15367620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-1-infected children on HAART: immunologic features of three different levels of viral suppression.
    Zaccarelli-Filho CA; Ono E; Machado DM; Brunialti M; Succi RC; Salomão R; Kallás EG; de Moraes-Pinto MI
    Cytometry B Clin Cytom; 2007 Jan; 72(1):14-21. PubMed ID: 17041945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progress and challenges in the use of latent HIV-1 reactivating agents.
    Shang HT; Ding JW; Yu SY; Wu T; Zhang QL; Liang FJ
    Acta Pharmacol Sin; 2015 Aug; 36(8):908-16. PubMed ID: 26027656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Suv39H1 methyltransferase inhibitor chaetocin causes induction of integrated HIV-1 without producing a T cell response.
    Bernhard W; Barreto K; Saunders A; Dahabieh MS; Johnson P; Sadowski I
    FEBS Lett; 2011 Nov; 585(22):3549-54. PubMed ID: 22020221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of Latent HIV-1 T Cell Reservoirs with a Combination of Innate Immune and Epigenetic Regulators.
    Palermo E; Acchioni C; Di Carlo D; Zevini A; Muscolini M; Ferrari M; Castiello L; Virtuoso S; Borsetti A; Antonelli G; Turriziani O; Sgarbanti M; Hiscott J
    J Virol; 2019 Nov; 93(21):. PubMed ID: 31413127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Valproic acid in association with highly active antiretroviral therapy for reducing systemic HIV-1 reservoirs: results from a multicentre randomized clinical study.
    Routy JP; Tremblay CL; Angel JB; Trottier B; Rouleau D; Baril JG; Harris M; Trottier S; Singer J; Chomont N; Sékaly RP; Boulassel MR
    HIV Med; 2012 May; 13(5):291-6. PubMed ID: 22276680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maraviroc Is Associated with Latent HIV-1 Reactivation through NF-κB Activation in Resting CD4
    Madrid-Elena N; García-Bermejo ML; Serrano-Villar S; Díaz-de Santiago A; Sastre B; Gutiérrez C; Dronda F; Coronel Díaz M; Domínguez E; López-Huertas MR; Hernández-Novoa B; Moreno S
    J Virol; 2018 May; 92(9):. PubMed ID: 29444937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In Vitro Reactivation of Replication-Competent and Infectious HIV-1 by Histone Deacetylase Inhibitors.
    Banga R; Procopio FA; Cavassini M; Perreau M
    J Virol; 2016 Feb; 90(4):1858-71. PubMed ID: 26656693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV-1 regulation of latency in the monocyte-macrophage lineage and in CD4+ T lymphocytes.
    Redel L; Le Douce V; Cherrier T; Marban C; Janossy A; Aunis D; Van Lint C; Rohr O; Schwartz C
    J Leukoc Biol; 2010 Apr; 87(4):575-88. PubMed ID: 19801499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Failure to reconstitute CD4+ T-cells despite suppression of HIV replication under HAART.
    Aiuti F; Mezzaroma I
    AIDS Rev; 2006; 8(2):88-97. PubMed ID: 16848276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. H3K27 Demethylation at the Proviral Promoter Sensitizes Latent HIV to the Effects of Vorinostat in Ex Vivo Cultures of Resting CD4+ T Cells.
    Tripathy MK; McManamy ME; Burch BD; Archin NM; Margolis DM
    J Virol; 2015 Aug; 89(16):8392-405. PubMed ID: 26041287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual role of prostratin in inhibition of infection and reactivation of human immunodeficiency virus from latency in primary blood lymphocytes and lymphoid tissue.
    Biancotto A; Grivel JC; Gondois-Rey F; Bettendroffer L; Vigne R; Brown S; Margolis LB; Hirsch I
    J Virol; 2004 Oct; 78(19):10507-15. PubMed ID: 15367617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple Histone Lysine Methyltransferases Are Required for the Establishment and Maintenance of HIV-1 Latency.
    Nguyen K; Das B; Dobrowolski C; Karn J
    mBio; 2017 Feb; 8(1):. PubMed ID: 28246360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral Gene Expression.
    Darcis G; Kula A; Bouchat S; Fujinaga K; Corazza F; Ait-Ammar A; Delacourt N; Melard A; Kabeya K; Vanhulle C; Van Driessche B; Gatot JS; Cherrier T; Pianowski LF; Gama L; Schwartz C; Vila J; Burny A; Clumeck N; Moutschen M; De Wit S; Peterlin BM; Rouzioux C; Rohr O; Van Lint C
    PLoS Pathog; 2015 Jul; 11(7):e1005063. PubMed ID: 26225566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo analysis of the effect of panobinostat on cell-associated HIV RNA and DNA levels and latent HIV infection.
    Tsai P; Wu G; Baker CE; Thayer WO; Spagnuolo RA; Sanchez R; Barrett S; Howell B; Margolis D; Hazuda DJ; Archin NM; Garcia JV
    Retrovirology; 2016 May; 13(1):36. PubMed ID: 27206407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ex Vivo Bioactivity and HIV-1 Latency Reversal by Ingenol Dibenzoate and Panobinostat in Resting CD4(+) T Cells from Aviremic Patients.
    Spivak AM; Bosque A; Balch AH; Smyth D; Martins L; Planelles V
    Antimicrob Agents Chemother; 2015 Oct; 59(10):5984-91. PubMed ID: 26169416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.